Strategic expansion Target expanding commercial footprint from Australia to the United States, focusing on hospital systems and healthcare networks in Florida where Next Science already has operations, presenting cross-border solution deployment and regional partnerships.

Clinical value Leverage evidence from pilot knee studies and the company’s focus on reducing biofilm-related infections to position BlastX and Xbio products as adjuncts for post-operative care, wound management, and infection prevention in surgical settings.

Board and governance Recent leadership changes and governance enhancements provide an opportunity to engage finance and strategy stakeholders for large-scale commercial initiatives, potential partnerships, and strategic investments.

Channel partnerships Existing collaborations with Oraderm, Arrotex Pharmaceuticals, and TerryWhite Chemmart create a foundation to expand through pharmacy, physician networks, and hospital procurement channels with bundled product offerings.

Financial readiness Mid-market revenue range and recent cash flow reporting indicate scalable growth potential; align sales messaging with mid-tier hospital systems and outpatient networks seeking cost-effective infection control solutions.